Thursday, Nov 30, 2023 · SEC filings
What the smart money revealed on Nov 30
409 insider filings came in. We hid 49 planned (10b5-1) sellers and 196 people whose filings were routine, like grants and tax withholding.
Pulse Biosciences (PLSE) Director Robert Duggan bought $1.12M
124,397 shares on the open market. Not a grant or an option exercise. Their past buys: 1 of 6 checked quarters beat the typical stock 6 months later.
Kayne Anderson Energy Infrastructure Fund (KYN) President James Baker bought $340K
40,000 shares on the open market. Not a grant or an option exercise. Their past buys: 4 of 8 checked quarters beat the typical stock 6 months later.
Sezzle (SEZL) Director Paul Purcell bought $253K
25,427 shares on the open market. Not a grant or an option exercise.
agilon health, inc. (AGL) Director Jeffrey Schwaneke bought $250K
22,300 shares on the open market. Not a grant or an option exercise.
Exxon Mobil (XOM) Director Jeffrey Ubben sold $216M
Not marked as a planned 10b5-1 sale. Sold every share held directly.
RxSight (RXST) Director Juliet Tammenoms Bakker sold $14.7M
Not marked as a planned 10b5-1 sale. Sold every share held directly.
Symbotic (SYM) Director Rollin Ford sold $3.88M
Not marked as a planned 10b5-1 sale. Sold every share held directly.
Show 44 more real buys
Show 92 more real sales
13F season
Holdings as of Sep 30, 2023 were due Nov 14
40 funds have filed. 40 filed for the quarter before.
Biggest real insider buys, Nov 24–30
Open-market buys by officers and directors, filed in the 7 days up to Nov 30.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.